SITAZIT M ER 500 10S

About

SITAZIT M ER 500 is a combination medication containing Sitagliptin and Metformin (extended-release), used in the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones (GLP-1 and GIP), which in turn enhance glucose-dependent insulin secretion and suppress glucagon release from the pancreas. Metformin, a biguanide, primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues.

This dual mechanism of action provides comprehensive glycemic control, addressing both insulin resistance and impaired insulin secretion. The extended-release formulation of Metformin helps to maintain stable drug levels throughout the day, potentially reducing gastrointestinal side effects. SITAZIT M ER 500 is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy is insufficient.

Uses

• Management of type 2 diabetes mellitus
• Improvement of glycemic control
• Reduction of fasting and post-prandial glucose levels
• Adjunct to diet and exercise

Directions For Use

Take one tablet orally once daily with the evening meal, as directed by your healthcare provider. Swallow the tablet whole; do not crush, chew, or break it.

Benefits

• Provides dual-action glycemic control
• Lowers HbA1c effectively
• Reduces risk of hypoglycemia (compared to sulfonylureas)
• Extended-release Metformin for sustained action
• May promote modest weight loss (Metformin component)
• Improves insulin sensitivity and secretion

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Upper respiratory tract infection
• Nasopharyngitis
• Hypoglycemia (especially with other agents)
• Pancreatitis (rare)
• Lactic acidosis (rare, Metformin)
• Joint pain
• Allergic reactions (rare)

Safety Measures

• Alcohol - Avoid excessive alcohol intake as it can increase the risk of lactic acidosis, a serious side effect associated with Metformin.
• Pregnancy - Consult a doctor. Generally not recommended during pregnancy unless clearly needed, as safety data are limited.
• Breastfeeding - Consult a doctor. Metformin is excreted in breast milk; Sitagliptin excretion is unknown. Weigh risks and benefits.
• Liver - Use with caution in patients with liver impairment; Metformin is contraindicated in severe hepatic dysfunction due to increased risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Dose adjustment is required for moderate impairment.
• Lung - Generally safe for lung conditions. However, patients with acute or chronic lung disease leading to hypoxemia may be at increased risk for lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.